nortriptyline has been researched along with Obesity in 3 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " To compare changes in body weight during treatment with different antidepressants, body weight and height were measured at baseline and after 6, 8, 12 and 26 wk treatment with escitalopram or nortriptyline in 630 adults with moderate-to-severe unipolar depression participating in GENDEP, a part-randomized open-label study." | 5.15 | Changes in body weight during pharmacological treatment of depression. ( Aitchison, KJ; Dernovsek, MZ; Farmer, A; Gray, JM; Hauser, J; Henigsberg, N; Kalember, P; Keers, R; Kozel, D; Larsen, ER; Maier, W; McGuffin, P; Mendlewicz, J; Mors, O; Placentino, A; Rietschel, M; Souery, D; Strohmaier, J; Szczepankiewicz, A; Uher, R; Zobel, A, 2011) |
| "Higher BMI and obesity predicted poor response to nortriptyline but did not significantly influence response to escitalopram." | 5.14 | Body weight as a predictor of antidepressant efficacy in the GENDEP project. ( Aitchison, KJ; Dernovsek, MZ; Farmer, A; Gunasinghe, C; Hauser, J; Henigsberg, N; Kalember, P; Kozel, D; Larsen, ER; Leszczynska-Rodziewicz, A; Linotte, S; Maier, W; McGuffin, P; Mors, O; Pedrini, L; Perroud, N; Placentino, A; Rietschel, M; Souery, D; Strohmaier, J; Uher, R; Zobel, A, 2009) |
| "The postulated therapeutic activity of nortriptyline metabolites has prompted investigation of dosage adjustments based on plasma levels of nortriptyline (NT) and its metabolites." | 1.28 | Relationships among nortriptyline, 10-OH(E)nortriptyline, and 10-OH(Z)nortriptyline steady-state plasma levels and nortriptyline dosage. ( Hurst, HE; Jones, DR; Lukey, BJ; Wright, JH, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uher, R | 2 |
| Mors, O | 2 |
| Hauser, J | 2 |
| Rietschel, M | 2 |
| Maier, W | 2 |
| Kozel, D | 2 |
| Henigsberg, N | 2 |
| Souery, D | 2 |
| Placentino, A | 2 |
| Perroud, N | 1 |
| Dernovsek, MZ | 2 |
| Strohmaier, J | 2 |
| Larsen, ER | 2 |
| Zobel, A | 2 |
| Leszczynska-Rodziewicz, A | 1 |
| Kalember, P | 2 |
| Pedrini, L | 1 |
| Linotte, S | 1 |
| Gunasinghe, C | 1 |
| Aitchison, KJ | 2 |
| McGuffin, P | 2 |
| Farmer, A | 2 |
| Keers, R | 1 |
| Gray, JM | 1 |
| Szczepankiewicz, A | 1 |
| Mendlewicz, J | 1 |
| Lukey, BJ | 1 |
| Jones, DR | 1 |
| Wright, JH | 1 |
| Hurst, HE | 1 |
2 trials available for nortriptyline and Obesity
| Article | Year |
|---|---|
Body weight as a predictor of antidepressant efficacy in the GENDEP project.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Appetite; | 2009 |
Changes in body weight during pharmacological treatment of depression.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Body Mass Index; Body Weight; Citalopram; Depressive | 2011 |
1 other study available for nortriptyline and Obesity
| Article | Year |
|---|---|
Relationships among nortriptyline, 10-OH(E)nortriptyline, and 10-OH(Z)nortriptyline steady-state plasma levels and nortriptyline dosage.
Topics: Body Weight; Humans; Nortriptyline; Obesity | 1989 |